A rose essential oil, a rose essential oil composition and rose essential oil gummies

Abstract

This invention provides a rose essential oil, a composition, and rose essential oil gummies, belonging to the field of immune-enhancing technology. The rose essential oil composition includes rose essential oil and excipients. The preparation method of the rose essential oil includes the following steps: adding rose petals and water to a distillation kettle, preheating with steam, and performing vacuum distillation after reaching a predetermined temperature, while maintaining the temperature of the oil-water separator to obtain rose essential oil. This invention provides a rose essential oil composition that realizes the purpose of developing application scenarios for roses and adding novel immune-enhancing compositions.

Description

Technical Field

[0001] This invention relates to the field of immune enhancement technology, specifically to a rose essential oil, a rose essential oil composition, and rose essential oil gummies. Background Technology

[0002] Immune cells are a core component of the human immune system, responsible for recognizing and eliminating pathogens and abnormal cells to maintain health. They mainly include T cells, B cells, NK cells, macrophages, and dendritic cells, which work together to form a multi-layered defense mechanism, divided into two main categories: innate immunity (non-specific) and adaptive immunity (specific). T cells are the core component of the immune system, maintaining health by recognizing and eliminating pathogens and regulating immune responses.

[0003] Regulating immune function includes immunosuppression and immune enhancement. In some cases, such as organ transplantation and the treatment of autoimmune diseases, immunosuppressants such as cyclosporine capsules, methylprednisolone tablets, leflunomide tablets, and cyclophosphamide can be chosen to suppress the body's immune response. Conversely, when immune enhancement is needed for conditions such as immunodeficiency, infection, or tumors, immune enhancers such as transfer factor oral solution, thymosin, levamisole hydrochloride tablets, lentinan, and interferon can be selected to enhance the body's immune capacity.

[0004] The existing immune enhancers mentioned above may cause side effects such as allergies, nausea, vomiting, loss of appetite, abdominal pain and diarrhea. Therefore, it is necessary to develop products that are both food and medicine. Summary of the Invention

[0005] In view of this, the present invention provides a rose essential oil to realize the application scenarios of rose and increase the number of novel immune-enhancing compositions.

[0006] To achieve the above objectives, the present invention provides a rose essential oil composition comprising rose essential oil and excipients.

[0007] Optionally, the rose essential oil accounts for 2 to 7% of the mass of the rose essential oil composition.

[0008] Optionally, the method for preparing rose essential oil includes the following steps: adding rose petals and water to a distillation kettle, preheating with steam, and performing vacuum distillation after reaching a predetermined temperature, while maintaining the temperature of the oil-water separator to obtain rose essential oil.

[0009] Optionally, the predetermined temperature is ≥98℃, the pressure in the distillation vessel during vacuum distillation is ≤90 kPa, the vacuum distillation time is 3~3.5h, and the temperature of the oil-water separator is 37~45℃.

[0010] Optionally, the excipients are starch and sucrose.

[0011] The rose essential oil composition also includes one or more of the following: snow chrysanthemum polysaccharide and levamisole.

[0012] Optionally, the snow chrysanthemum polysaccharide accounts for 2-5% of the mass of the rose essential oil composition.

[0013] For the above purposes, the present invention provides a rose essential oil composition for preparing an immune-enhancing drug.

[0014] Optionally, the rose essential oil composition functions to repair intestinal glandular epithelial cells.

[0015] To achieve the above objectives, the present invention also provides a rose essential oil soft candy comprising the above-described rose essential oil composition.

[0016] The above-described technical solution of the present invention has at least the following beneficial effects: The present invention provides a rose essential oil composition that is both medicinal and edible. According to the results of flow cytometry detection of the ratio of immune cells in the spleen and related experimental results, the rose essential oil composition provided by the present invention can restore immune function after immunosuppression. Furthermore, the rose essential oil composition of the present invention has a significantly better repair effect on intestinal glandular epithelial cells than the immune enhancers in the prior art. Attached Figure Description

[0017] Figure 1 This is a graph showing the percentage of CD45+ and CD3+ indicators in each group during the experiment of this invention. Figure 2 This is a graph showing the levels of IL-10 and TNF-α in each group during the experiments of this invention. Figure 3 This is a graph showing the intestinal gland depth index of each group in the experiment of this invention; Figure 4 A 40x magnified section of mouse intestinal tissue from the blank control group; Figure 5 A 40x magnified image of the intestinal tissue section of the model group mice; Figure 6 A 40x magnified section of mouse intestinal tissue from the positive control group; Figure 7 A 40x magnified section of intestinal tissue from mice in the low-dose rose essential oil group; Figure 8 This is a 40x magnified image of the intestinal tissue of mice in the high-dose rose essential oil group. Detailed Implementation

[0018] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the following will be described in conjunction with the accompanying drawings of the embodiments of the present invention. Figures 1-8The technical solutions of the embodiments of the present invention will be clearly and completely described herein. Obviously, the described embodiments are only a part of the embodiments of the present invention, and not all of them. All other embodiments obtained by those skilled in the art based on the described embodiments of the present invention are within the scope of protection of the present invention.

[0019] Example 1 This invention provides a rose essential oil composition comprising rose essential oil, sucrose, and starch. The rose essential oil accounts for 5% of the mass of the rose essential oil composition.

[0020] The method for preparing rose essential oil provided by the present invention includes: putting rose petals and water into a distillation kettle, preheating with steam, performing vacuum distillation after reaching a predetermined temperature, maintaining the temperature of the oil-water separator, and obtaining rose essential oil.

[0021] The specific method for preparing rose essential oil is as follows: The TU130 rose essential oil equipment has an exhaust valve on the distillation vessel. Before processing essential oil, open this valve first, then close the drain butterfly valve below the distillation vessel to ensure no air leakage and no water flow. Open the V-shaped door at the feed inlet and add material to the distillation vessel. The material volume should be about 2 / 3 of the total volume of the distillation vessel to be considered qualified and ready for further processing (the specific weight is approximately 500 kg).

[0022] 2. Add water during distillation The water volume for the TU130 essential oil dispenser should be controlled at around 200 kg. It is best to install a water meter on the water supply pipe. If there is no water meter, the water volume should generally be determined by filling the pipe 10 cm above the outlet pipe.

[0023] 3. Heating distillation 3.1 Before introducing steam, check whether the feed port of the distillation vessel is closed and whether the exhaust valve is open. Cold air needs to be vented. When adding steam, first add 1 / 3 of the total air volume of the pipeline through the valve, and preheat for about 40 minutes.

[0024] 3.2 After timing for 40 minutes, increase the steam flow by 1 / 3. When the exhaust valve on the distillation vessel begins to release steam, start recording the distillation time, and close the exhaust valve on the distillation vessel. Begin adjusting the valve to maintain 2 / 3 of the steam flow for 2.5 hours, referring to the temperature gauge on the distillation vessel. Once the steam temperature reaches the predetermined temperature, begin normal distillation. The predetermined temperature is above 98 degrees Celsius, and it typically reaches the predetermined temperature after 1.0 hour of heating.

[0025] 3.3 The gas supply pressure of the pressure pack should be above 2 kg, the gas supply from the boiler should be no less than 3 kg, and the pressure inside the distillation vessel should be below 0.9 kg (i.e., ≤90 kPa), which is beneficial for the extraction of rose aromatics. Reduced pressure distillation is adopted. When the distillation time exceeds 3.0 hours, the gas pressure is adjusted to the maximum, and the time is maintained for 40 minutes. The entire distillation process, from flower loading to distillation completion, takes 4 hours.

[0026] 4. Condensation When steam is discharged from the exhaust valve on the distillation vessel, begin to open the water supply valve on the condenser, opening it to approximately half capacity. Maintain the temperature gauge reading on the oil-water separator between 37-45°C. If the temperature is too high, increase the water flow; if the temperature is below 37°C, decrease the water flow. When the distillation time is complete (based on the recorded start time), close the gas supply valve, but do not close the cooling water supply valve. Generally, close the cooling water 10 minutes later.

[0027] 5. Operation of the oil-water separator The return water pipe on the oil-water separator has no return water for the first 40 minutes of distillation. When return water begins to flow, open the return valve to allow the return pipe to automatically circulate the water. The circulated rose hydrosol returns to the distillation tower. After 2.5 hours of distillation, close the return valve, and rose hydrosol will begin to flow out. At this point, the oil-water separator is almost full of rose hydrosol. You can then open the valve at the bottom of the oil-water separator to start releasing the rose hydrosol. Generally, leave 1 / 3 of the rose hydrosol at the bottom of the oil-water separator. Remember not to release all the rose hydrosol at once to prevent the rose essential oil from flowing out.

[0028] 6. Discharge Before discharging, first close the gas supply valve of the steam separator, then close the gas supply valve of the distillation kettle, close the condensate supply valve, open the air vent valve on top of the distillation kettle, and open the water supply valve to the distillation kettle to allow cold water to enter the distillation kettle. Once everything is ready, open the drain valve at the bottom of the distillation kettle to start discharging. The discharging time is generally 15 minutes. While discharging, rinse the distillation tank and distillation tower with cold water. Generally, from feeding to discharging, it takes about 5.5 hours. The entire distillation is then complete, and the next cycle begins.

[0029] 7. Extracting rose essential oil When there is too much rose essential oil in the oil cup on the oil-water separator, you can start extracting the rose essential oil. When extracting the rose essential oil, operate the reflux valve with one hand to let the reflux water enter the oil-water separator, causing the rose essential oil level to rise. When it rises to a certain level, the rose essential oil will start to flow out from the drain pipe. Place a larger container under the bottle containing the rose essential oil to prevent the rose essential oil from overflowing and being wasted.

[0030] Example 2 This invention provides a rose essential oil composition comprising rose essential oil, sucrose, and starch. The rose essential oil accounts for 2% of the mass of the rose essential oil composition.

[0031] The method for preparing rose essential oil provided by this invention includes: adding rose petals and water to a distillation kettle, preheating with steam, and performing vacuum distillation after reaching a predetermined temperature, while maintaining the temperature of the oil-water separator to obtain rose essential oil. The specific operation is consistent with Example 1.

[0032] Example 3 This invention provides a rose essential oil composition comprising rose essential oil, sucrose, and starch. The rose essential oil accounts for 3% of the mass of the rose essential oil composition.

[0033] The method for preparing rose essential oil provided by this invention includes: adding rose petals and water to a distillation kettle, preheating with steam, and performing vacuum distillation after reaching a predetermined temperature, while maintaining the temperature of the oil-water separator to obtain rose essential oil. The specific operation is consistent with Example 1.

[0034] Example 4 This invention provides a rose essential oil composition comprising rose essential oil, snow chrysanthemum polysaccharide, sucrose, and starch. The rose essential oil comprises 7% of the rose essential oil composition by mass, and the snow chrysanthemum polysaccharide comprises 2.5% of the rose essential oil composition by mass.

[0035] The preparation method of rose essential oil is the same as in Example 1.

[0036] Example 5 The present invention provides a rose essential oil composition comprising rose essential oil, levamisole, sucrose, and starch.

[0037] Example 6 The present invention provides a rose essential oil soft candy comprising a rose essential oil composition.

[0038] Comparative Example 1 Compared to Example 1, the only difference is that the rose essential oil in the rose essential oil composition is replaced with levamisole.

[0039] Mouse experiments with rose essential oil compositions I. Experimental Methods (I) Model Construction SPF-grade male BALB / c mice (8 weeks old, weighing 20±2g), 10 mice per group, 6 groups in total: 1. Control group: normal saline administered by gavage (0.2 mL / d) + normal saline administered by intraperitoneal injection; 2. Model group (CTX): normal saline by gavage + cyclophosphamide (150mg / kg / day, intraperitoneal injection, for 3 consecutive days); 3. Positive control group (levamisole): Levamisole (5 mg / kg / d) administered by gavage + cyclophosphamide; 4. Low-dose rose essential oil group: Rose essential oil (100mg / kg / d) administered by gavage + cyclophosphamide; 5. High-dose rose essential oil group: Rose essential oil (200mg / kg / d) was administered by gavage + cyclophosphamide.

[0040] Cyclophosphamide is an immunosuppressant, while levamisole is an immunostimulant.

[0041] (II) Intervention Cycle 1. Seven-week-old mice were acclimatized for one week. Cyclophosphamide was administered via gavage starting on day 4 after injection and continued for 28 days.

[0042] 2. After the intervention, the patient was kept fasting for 12 hours, anesthetized with 10% chloral hydrate, blood was drawn and the patient was euthanized, and the tissue was immediately separated.

[0043] (III) Testing Indicators Flow cytometry analysis of CD45+ and CD3+ markers is used to determine different immune cell populations and their functional status.

[0044] The level of serum inflammatory factors (TNF-α and IL-10) is detected by enzyme-linked immunosorbent assay (ELISA) to assess the immune function. IL-10 is an anti-inflammatory factor, and TNF-α is a pro-inflammatory factor.

[0045] The condition of the intestines can be determined by examining the depth of the intestinal glands and by examining sections of intestinal tissue.

[0046] II. Experimental Results (a) CD45+ and CD3+ indicators Figure 1 The chart shows the percentage of CD45+ and CD3+ indicators in each of the above groups.

[0047] Depend on Figure 1 It can be seen that, with the blank control group as the baseline, the CD45+ index in the model group was lower than that in the blank control group, that is, cyclophosphamide reduced the CD45+ index; the CD45+ index in the positive control group was higher than that in the blank control group, that is, levamisole increased the CD45+ index; the CD45+ index in the positive control group > the high-dose rose essential oil group > the low-dose rose essential oil group > the blank control group, that is, the rose essential oil provided by the present invention has the effect of increasing the CD45+ index after being subjected to the immunosuppressant cyclophosphamide, and the effect of increasing the CD45+ index is close to that of the immune enhancer levamisole.

[0048] Depend on Figure 1It can be seen that, with the blank control group as the baseline, the CD3+ index in the model group was lower than that in the blank control group, that is, cyclophosphamide reduced the CD3+ index; the CD3+ index in the positive control group was lower than that in the blank control group, but higher than that in the model group, that is, levamisole played a role in restoring the CD3+ index; the CD3+ index in the high-dose rose essential oil group > the positive control group > the low-dose rose essential oil group > the model group, that is, the rose essential oil provided by this invention has the effect of improving the CD3+ index after being exposed to the immunosuppressant cyclophosphamide, and the effect of improving the CD3+ index is better than that of the immune enhancer levamisole.

[0049] In summary, the rose essential oil provided by this invention can restore CD45+ and CD3+ levels to normal or higher after being subjected to immunosuppressants. That is, the rose essential oil provided by this invention can promote the recovery of overall T cell immune function as well as the recovery of overall white blood cell count and immune system size.

[0050] (II) Serum inflammatory factors Figure 2 The graph shows the levels of IL-10 and TNF-α in each of the above groups.

[0051] Depend on Figure 2 It can be seen that, with the blank control group as the baseline, the IL-10 index in the model group was lower than that in the blank control group, that is, cyclophosphamide reduced the anti-inflammatory factor index; the IL-10 index in the positive control group was lower than that in the blank control group, but higher than that in the model group, that is, levamisole played a role in restoring the anti-inflammatory factor index; the CD3+ index of the high-dose rose essential oil group > the low-dose rose essential oil group > the positive control group > the blank control group > the model group, that is, the rose essential oil provided by the present invention has the effect of relieving the inhibition of anti-inflammatory factor index by the immunosuppressant cyclophosphamide, and the effect of improving the anti-inflammatory factor index is better than that of the immune enhancer levamisole.

[0052] Depend on Figure 2 It can be seen that, with the blank control group as the baseline, the TNF-α index in the model group was higher than that in the blank control group, that is, cyclophosphamide increased the pro-inflammatory factor index; the TNF-α index in the positive control group was higher than that in the blank control group, but lower than that in the model group, that is, levamisole played a role in inhibiting the increase of pro-inflammatory factor index; the TNF-α index in the model group > the low-dose rose essential oil group > the positive control group > the low-dose rose essential oil group > the blank control group, that is, the rose essential oil provided by the present invention has the effect of inhibiting the increase of pro-inflammatory factor index brought about by the immunosuppressant cyclophosphamide, and the effect of inhibiting the pro-inflammatory factor index is better than that of the immune enhancer levamisole.

[0053] In summary, the rose essential oil provided by this invention can restore the level of the anti-inflammatory factor IL-10 to normal or higher after being subjected to immunosuppressants, and reduce the level of the pro-inflammatory factor TNF-α after being subjected to immunosuppressants. That is, the rose essential oil provided by this invention can promote the recovery of anti-inflammatory factors, inhibit the increase of pro-inflammatory factors, and improve overall immunity.

[0054] (III) Intestinal gland indicators Figure 3 The above figures show the intestinal gland depth index for each group.

[0055] Depend on Figure 3 It can be seen that the colonic glands in the blank control group were at normal depth. Compared with the colonic gland depth in the blank control group, the intestinal gland depth in the model group was significantly reduced, indicating that cyclophosphamide damaged the epithelial cells of the intestinal glands, leading to intestinal gland atrophy. The intestinal gland depth in the positive control group was close to that in the blank control group, indicating that levamisole can restore intestinal gland atrophy. The intestinal gland depth in the low-dose rose essential oil group was close to that in the positive control group. The intestinal gland depth in the high-dose rose essential oil group was > blank control group > positive control group > low-dose rose essential oil group > model group. This means that rose essential oil can restore intestinal gland atrophy caused by the immunosuppressant cyclophosphamide, and its effect is better than that of the immunostimulant levamisole.

[0056] Figure 4 A 40x magnified section of mouse intestinal tissue from the blank control group; Figure 5 A 40x magnified image of the intestinal tissue section of the model group mice; Figure 6 A 40x magnified section of mouse intestinal tissue from the positive control group; Figure 7 A 40x magnified section of intestinal tissue from mice in the low-dose rose essential oil group; Figure 8 This is a 40x magnified image of the intestinal tissue of mice in the high-dose rose essential oil group.

[0057] Depend on Figure 4 You can see healthy, undamaged colonic mucosa with intact intestinal gland structure and epithelial cell proliferation and apoptosis in a balanced state.

[0058] Depend on Figure 5 As can be seen, the mice in the model group injected with cyclophosphamide exhibited intestinal gland atrophy and intestinal mucosal damage. This means that cyclophosphamide, as an immunosuppressant, kills a large number of actively proliferating intestinal gland epithelial cells, inhibits cell regeneration, leading to intestinal gland atrophy, shallowing of the glands, and intestinal mucosal damage.

[0059] Depend on Figure 6 As can be seen, when the immunosuppressant cyclophosphamide was administered concurrently with the immunostimulant levamisole via gavage, the intestinal gland structure remained intact and the colonic mucosa was normal. This indicates that levamisole can indirectly promote the repair and regeneration of the intestinal epithelium by improving the overall immune status, thereby reversing the intestinal gland atrophy induced by cyclophosphamide.

[0060] Depend on Figure 7It can be seen that when a low dose of rose essential oil was administered by gavage while simultaneously injecting the immunosuppressant cyclophosphamide, the intestinal gland structure remained intact and the colonic mucosa was normal.

[0061] Depend on Figure 8 It can be seen that when the immunosuppressant cyclophosphamide was injected simultaneously with a high dose of rose essential oil administered by gavage, the intestinal gland structure remained intact and the colonic mucosa was normal.

[0062] Combination Figures 4 to 8 It is known that the rose essential oil provided by this invention has similar effects on repairing intestinal mucosal damage and intestinal gland structure compared with the immune enhancer levamisole.

[0063] The above are preferred embodiments of the present invention. It should be noted that, for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A rose essential oil composition, characterized in that, The rose essential oil composition includes rose essential oil and excipients.

2. The rose essential oil composition according to claim 1, characterized in that, The rose essential oil accounts for 2-7% of the mass of the rose essential oil composition.

3. The rose essential oil composition according to claim 1, characterized in that, The method for preparing rose essential oil includes the following steps: adding rose petals and water into a distillation kettle, preheating with steam, and performing vacuum distillation after reaching a predetermined temperature, while maintaining the temperature of the oil-water separator to obtain rose essential oil.

4. The rose essential oil composition according to claim 1, characterized in that, The predetermined temperature is ≥98℃, the pressure in the distillation vessel during vacuum distillation is ≤90 kPa, the vacuum distillation time is 3~3.5h, and the temperature of the oil-water separator is 37~45℃.

5. The rose essential oil composition according to claim 1, characterized in that, The auxiliary materials also include starch and sucrose.

6. The rose essential oil composition according to claim 1, characterized in that, The rose essential oil composition also includes one or more of the following: snow chrysanthemum polysaccharide and levamisole.

7. The rose essential oil composition according to claim 1, characterized in that, The snow chrysanthemum polysaccharide accounts for 2-5% of the mass of the rose essential oil composition.

8. A rose essential oil composition as described in any one of claims 1-7 for use in the preparation of an immune-enhancing medicament.

9. The rose essential oil composition according to claim 8 is used to prepare an immune-enhancing drug, characterized in that, The rose essential oil composition is used to repair intestinal gland epithelial cells.

10. A rose essential oil soft candy, characterized in that, Includes the rose essential oil composition of claim 1.

Images